Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.60
+4.4%
$2.20
$0.40
$3.10
$200.75M2.052.21 million shs3.71 million shs
Galecto, Inc. stock logo
GLTO
Galecto
$3.49
+2.5%
$3.18
$2.01
$16.07
$4.50M1.3585,372 shs14,494 shs
Kamada Ltd. stock logo
KMDA
Kamada
$8.02
+2.2%
$7.13
$5.08
$9.16
$461.19M0.9695,891 shs99,793 shs
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
$2.23
$2.22
$1.29
$3.65
$127.82M1.7724,253 shsN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$2.43
-2.4%
$2.29
$1.90
$4.21
$72.60M0.61186,497 shs218,611 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+4.42%+4.42%-3.70%+388.26%+98.47%
Galecto, Inc. stock logo
GLTO
Galecto
+2.50%+1.01%+3.72%+50.22%-72.18%
Kamada Ltd. stock logo
KMDA
Kamada
+2.17%+3.40%+14.74%+32.13%+35.93%
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-2.41%+20.00%+1.67%+14.62%-30.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.2219 of 5 stars
3.51.00.04.72.11.71.3
Galecto, Inc. stock logo
GLTO
Galecto
3.289 of 5 stars
3.55.00.00.00.71.71.3
Kamada Ltd. stock logo
KMDA
Kamada
3.7335 of 5 stars
3.33.00.00.02.71.72.5
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.6191 of 5 stars
0.05.00.00.01.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33105.13% Upside
Galecto, Inc. stock logo
GLTO
Galecto
3.00
Buy$10.00186.94% Upside
Kamada Ltd. stock logo
KMDA
Kamada
2.67
Moderate Buy$13.0062.09% Upside
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
0.00
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest VTGN, CTMX, PRTK, KMDA, and GLTO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/14/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M1.52$0.38 per share6.88($0.01) per share-260.00
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/A$10.99 per shareN/A
Kamada Ltd. stock logo
KMDA
Kamada
$160.95M2.87$0.50 per share15.97$4.51 per share1.78
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
$160.27M0.80N/AN/A($3.08) per share-0.72
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$490K144.61N/AN/A$2.44 per share1.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.485.42N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)
Galecto, Inc. stock logo
GLTO
Galecto
-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2927.6625.060.959.60%6.31%4.43%8/13/2025 (Estimated)
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
-$63.57M-$1.10N/AN/A-35.44%N/A-40.05%N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)

Latest VTGN, CTMX, PRTK, KMDA, and GLTO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
5/8/2025Q1 2025
Galecto, Inc. stock logo
GLTO
Galecto
N/A-$1.92N/A-$1.92N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.73
1.73
Galecto, Inc. stock logo
GLTO
Galecto
N/A
9.62
9.62
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
N/A
0.52
0.46
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
6.51
6.51

Institutional Ownership

CompanyInstitutional Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Galecto, Inc. stock logo
GLTO
Galecto
14.20%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
53.60%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
Galecto, Inc. stock logo
GLTO
Galecto
10.80%
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
8.00%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million75.30 millionOptionable
Galecto, Inc. stock logo
GLTO
Galecto
401.32 million1.18 millionOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
Paratek Pharmaceuticals, Inc. stock logo
PRTK
Paratek Pharmaceuticals
26857.32 million52.74 millionOptionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4029.16 million28.78 millionOptionable

Recent News About These Companies

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.60 +0.11 (+4.42%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$2.62 +0.02 (+0.96%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Galecto stock logo

Galecto NASDAQ:GLTO

$3.48 +0.09 (+2.50%)
Closing price 07/10/2025 03:45 PM Eastern
Extended Trading
$3.48 0.00 (0.00%)
As of 07/10/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Kamada stock logo

Kamada NASDAQ:KMDA

$8.02 +0.17 (+2.17%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$8.02 0.00 (0.00%)
As of 08:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Paratek Pharmaceuticals stock logo

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$2.43 -0.06 (-2.41%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$2.42 -0.01 (-0.21%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.